| Patient | Jacqueline Mary du Pré |
|---|---|
| Date of birth | 1945-01-26 |
| Identifiers | MRN HR-ML039-SYN-TD; SSN (made up) 000-39-7062 |
| Document date | 1973-09-14 |
| Author | Imogen Thackeray-Osei, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Periodic adult preventive visit. [S]
Ms. du Pré, 28, comes for her yearly preventive visit five months after starting ocrelizumab. She has had no relapse; the cystitis in June cleared with nitrofurantoin and the tingling that came with it went within two days. She practices three to four hours a day, played chamber music in public last month for the first time this year, and teaches two students a week. Fatigue comes in the late afternoon and she plans her day around it. She takes cholecalciferol 4000 units daily. Her PHQ-9 today is 3. [S]
| Element | Detail |
|---|---|
| Visit | Periodic adult preventive visit, age 28 |
| Active conditions | Relapsing-remitting multiple sclerosis on ocrelizumab; vitamin D deficiency on replacement |
| Medicines | Ocrelizumab every six months (next dose next month); cholecalciferol 4000 units daily |
| Mood | PHQ-9 3 |
Health risk assessment. Completed by the patient on a tablet in the waiting room and reviewed with her by Dr. Thackeray-Osei. [S]
| Domain | Finding |
|---|---|
| Self-rated health | Good, and much better than in the spring |
| Psychosocial | Busy with practice, teaching and concerts; worries about another relapse; good support from friends |
| Tobacco | Never smoked |
| Alcohol and drugs | A glass of wine two or three evenings a week; no drugs |
| Physical activity | Swims twice a week and walks daily, as the occupational therapist suggested for fatigue |
| Nutrition | Regular meals; no restrictions |
| Sleep | Eight hours; rests for half an hour after lunch |
| Sexual and reproductive health | Condoms used consistently; not planning a pregnancy this year |
| Safety at home | Feels safe; no one hurts, threatens or controls her |
| Road safety | Wears a seat belt; does not drive when tired |
| Activities of daily living | Independent |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Late-afternoon fatigue, managed with pacing; no fever or weight loss |
| Eyes | Negative | No blurred vision or pain on moving the eyes |
| Ears, nose, mouth, and throat | Negative | No hearing change |
| Cardiovascular | Negative | No chest pain or palpitations |
| Respiratory | Negative | No cough or breathlessness |
| Gastrointestinal | Negative | Bowels regular |
| Genitourinary | Negative | No urgency or burning since June |
| Breast | Negative | No lump |
| Musculoskeletal | Negative | Some neck and shoulder stiffness after long practice |
| Integumentary | Negative | No rash or changing moles |
| Neurological | Positive | Faint tingling in the left fingertips after long practice; no weakness or imbalance |
| Psychiatric | Negative | Mood good; PHQ-9 3; no thoughts of self-harm |
12 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Nitrofurantoin macrocrystals 100 mg oral capsule, one capsule by mouth twice daily with food for 5 days | One capsule twice daily for 5 days | Oral route | 1973-06-15 to 1973-06-19 | completed | S |
| Methylprednisolone 1000 mg injection, 1 g intravenously over one hour once daily for 3 days | 1 g daily for 3 days | Intravenous route | 1973-03-24 to 1973-03-26 | completed | S |
| Cholecalciferol (vitamin D3) 4000 unit (100 microgram) oral capsule, one capsule by mouth daily | One capsule daily | Oral route | 1973-03-23 | active | S |
| Ocrelizumab 30 mg/mL injection: first dose as 300 mg intravenously on day 1 and day 15, then 600 mg intravenously every 6 months, with methylprednisolone 100 mg, an antihistamine and acetaminophen before each infusion | 300 mg on days 1 and 15, then 600 mg every 6 months | Intravenous route | 1973-04-13 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1973-09-14 | Body height | 173 | cm | S |
| 1973-09-14 | Body weight | 63.9 | kg | S |
| 1973-09-14 | Body mass index (BMI) [Ratio] | 21.4 | kg/m2 | S |
| 1973-09-14 | Systolic blood pressure | 110 | mm[Hg] | S |
| 1973-09-14 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 1973-09-14 | Heart rate | 68 | /min | S |
| 1973-09-14 | Respiratory rate | 14 | /min | S |
| 1973-09-14 | Body temperature | 36.6 | Cel | S |
| 1973-09-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1973-09-14 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S |
Vital signs recorded on 1973-09-14; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| Constitutional | Well; weight 63.9 kg, BMI 21.4; blood pressure 110/70 |
| Head, eyes, ears, nose, and throat | Normal; fundi normal |
| Neck | No lymph nodes; thyroid normal |
| Breasts | Examined with her agreement and a chaperone: no mass or nipple discharge; no axillary nodes |
| Cardiovascular | Regular rhythm; no murmur |
| Respiratory | Clear to auscultation bilaterally |
| Abdomen | Soft, non-tender |
| Skin | No rash; no suspicious moles |
| Musculoskeletal | Tight upper trapezius muscles; full neck movement |
| Neurological | Vibration slightly reduced in the left fingertips only; strength, reflexes and gait normal |
| Psychiatric | Bright, warm and engaged |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Numbness, tingling and loss of position sense in the fingers of both hands for three weeks, worse on the left, with clumsiness that makes her lose her place on the fingerboard, an electric feeling down the spine on bending the neck (Lhermitte's sign), and fatigue; a similar month of tingling in the fingers 18 months ago settled on its own. A lesion of the cervical spinal cord must be found: MRI of the brain and spine with contrast booked this week | resolved | confirmed | R20.2 | S — Synthetic presenting problem anchored to her documented loss of sensation in her fingers and fatigue. Superseded by the diagnosis at the second visit. |
| Relapsing-remitting multiple sclerosis, active: a current relapse (partial cervical myelitis at C3 to C4 with sensory loss and clumsiness of the hands) after an earlier sensory episode; dissemination in space and time on MRI, with an enhancing cord lesion and an enhancing brain lesion; CSF-specific oligoclonal bands; aquaporin-4 antibody negative; meets the 1964 McDonald criteria and the 1971 revision; synthetic modern detail linked to her documented diagnosis | active | confirmed | G35.A | S — Synthetic course, imaging and laboratory detail; linked to her documented diagnosis in October 1973. |
| Vitamin D deficiency: 25-hydroxyvitamin D 16 ng/mL; replacement to correct the deficiency, not as a treatment for multiple sclerosis | active | confirmed | E55.9 | S — Synthetic finding. |
| Acute uncomplicated cystitis (Escherichia coli) seven weeks after the first ocrelizumab course, with a pseudo-relapse: two days of returning tingling in the fingers with a low fever and no new neurological deficit; resolved | resolved | confirmed | N30.00 | S — Synthetic intercurrent infection; not a historical claim. |
Personalized prevention plan. A written copy was given to the patient. [S]
| Service | Status | Detail |
|---|---|---|
| Blood pressure screening | Completed today | 110/70 mmHg |
| Depression screening | Completed today | PHQ-9 score 3; item 9 scored 0 |
| Unhealthy alcohol use screening | Completed today | Two or three glasses of wine a week; low risk |
| Tobacco use | Completed today | Never smoked |
| Intimate partner violence screening | Completed today | Negative; she feels safe |
| Cervical cancer screening | Up to date | Cytology two years ago normal; next at three years |
| Chlamydia and gonorrhea screening | Not indicated | Over 24 and not at increased risk |
| HIV, hepatitis B and hepatitis C screening | Up to date | All negative before treatment |
| Influenza vaccine | Completed today | Inactivated vaccine, about five weeks before the next ocrelizumab dose |
| COVID-19 vaccine | Completed today | This season's mRNA vaccine |
| Pneumococcal vaccine | Up to date | PCV20 before treatment, for an adult starting immunosuppressive therapy |
| Recombinant zoster vaccine | Up to date | Two doses, before and during treatment |
| Hepatitis B vaccine | Due | Two doses given; the surface antibody check after the series is due with next month's blood tests |
| HPV vaccine | Up to date | Series completed in adolescence |
| Tetanus, diphtheria, and pertussis | Up to date | Tdap three years ago |
| Live vaccines (MMR, varicella) | Not indicated | Immune to measles and varicella; live vaccines are avoided on ocrelizumab |
| Contraception counseling | Completed today | Condoms used consistently; IUD or implant offered for more reliable protection during treatment |
| Dental and vision examination | Due | Dental check due; eye examination normal today on fundoscopy, optometry yearly |
Immunizations given today: Influenza vaccine, this season (inactivated); COVID-19 mRNA vaccine, this season's formula [S]
Guideline basis: Farez MF, et al. Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis. Neurology 2019;93(13):584-594 (PMID 31462584) (2019); Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); USPSTF A and B Recommendations (2026); Cervical Cancer: Screening (2018); Adult Immunization Schedule by Medical Condition and Other Indication (2026)
Follow-up: Ocrelizumab 600 mg next month with blood tests and hepatitis B surface antibody beforehand. Cervical screening next year. Next preventive visit in one year. Next scheduled visit 1973-10-12: six months: first 600 mg dose of ocrelizumab, no evidence of disease activity, immunoglobulins, vaccination response, pregnancy planning and her return to performing. [S]
Voluntary advance care planning discussion of about 15 minutes, with her consent. She named a health care agent, recorded in the confidential part of the chart and not named here. She said that she wants to be told plainly about her illness and its treatment, that she wants every treatment that can keep her playing and independent, and that if she were ever too ill to decide she would want her wishes about music and comfort respected. To be revisited at each change in her health and at least yearly. [S]